| HOME >> BIOLOGY >> TECHNOLOGY |
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
Introduction II-1
Bladder Cancer Growing at an Alarming Rate II-1
Bladder Cancer Statistics II-1
Table 1: Worldwide Incidence of Bladder Cancer by Select
Countries/Region (2003 & 2013): US, Europe, and Japan (In
'000s) (includes corresponding Graph/Chart) II-1
Table 2: Worldwide Incidence and Mortality Rates of Select
Cancer Types in Males: 2007 (includes corresponding
Graph/Chart) II-2
Table 3: Incidence and Mortality Rates of Select Cancer Types
in Industrialized Countries: 2007 (includes corresponding
Graph/Chart) II-3
Table 4: Incidence and Mortality Rates of Select Cancer Types
in Developing Markets: 2007 (includes corresponding
Graph/Chart) II-4
Recurrent Nature: A Major Cause of Concern II-4
Bladder Cancer: The Most Costly Cancer To Treat II-5
Generics Characterize Bladder Cancer Market II-5
Existing Drug Therapies Lack in Assuring Long Term Survival Rate II-5
Approved Intravesical Agents for Bladder Cancer II-6
Bladder Cancer Demands New Therapeutics to Fill the Void II-6
Table 5: Number of Pipeline Drugs by Select Cancer Types
(includes corresponding Graph/Chart) II-7
What the Future Holds? II-7
Table 6: World Market for Bladder Cancer Therapeutics (2008):
Percentage Share Breakdown of Total Number of Drugs by
Development Stage (includes corresponding Graph/Chart) II-7
Emerging Therapeutic Options for Superficial Bladder Cancer II-8
Table 7: EOquin Penetration Rate in the US for the Years
2011 through 2015 (includes corresponding Graph/Chart) II-8
Table 8: US Market for EOquin: Annual Revenue Projections
for the Years 2011 through 2015 in US$ Mi
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |